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Apnea of prematurity is associated with high morbidity and mortality. Treatment 
generally includes supplemental oxygen and theophylline or caffeine. The half- 
life of theophylline is prolonged in newborns because of their immature 
cytochrome P-450 system, and there is considerable variation in the drug’s 
metabolism in infants. We compared the accuracy, precision, and reliability of 
two equations that use postnatal age (PNA) to determine a maintenance dosage 
of theophylline with a standard mainlenance dosage (SMD) that produced a 
steady-state serum theophylline concentration (STC) of 8 pg/ml for ap‘nea of 
prematurity in 46 infants less than 34 weeks’ geslational age (GA) and less than 
36 weeks’ postconceptional age (PCA). The two equations were mg/kg/day = 
[(0.2 x PNA in wks) + 51, and mg/kg/day = [(0.3 x PNA in wks) + 81. Their 
reliability to predict the SMD was determined by correlation analysis. The 
precision and accuracy with which they predicted SMD were determined and 
analyzed by x’. The SMD did not correlate with the maintenance dosages 
calculated by equations 1 and 2 (r=0.296 and 0.296, p>0.05 in both cases). 
Multiple linear regression of SMD versus GA , PNA, and PCA was not significant 
(r=0.33, p=0.32). After stratifying data based on GA and performing correlation 
analysis of SMD versus PNA, a weak but significant correlation (r=0.42,  
p=0.0517) was found for infants with GA between 31 and 34 weeks. Poor 
correlation was found between SMD versus PNA for infants 27-30 weeks’ GA. 
Two new equations of the best fit line were generated using the same data. 
Currently available equat ions for determining maintenance dosages of 
theophylline in infants and children are not reliable for premature newborns, in 
whom two new equations based on GA and PNA have been developed. The 
equations will be evaluated for their utility, and employed to accrue data to 
determine if better ones can be developed. 
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Because of its associated high morbidity and 
mortality, apnea of prematurity is of major concern 
in preterm infants, of premature infants weighing 
less than 2500 g at birth, 25% will experience at 
least one episode of apnea, which increases to 84% 
for infants weighing under 1000 g . ’  Morbidity 
and  mortality increase with the number  and 
durat ion (> 20 set) of apneic  episodes,’ 7he  
disorder has many possible etiologies in infants; 
247 
however, the most probable one is an under-  
developed medullary respiratory center that docs 
n 6 t ad e qu a t e 1 y respond to h y p sxi a and h y I-, c r- 
capnia.i 
Treatment 0 1  apnea  may b c  suppor t i \*e  o r  
p 11 arm a c CI 1 o gi c . S u 11 p o 1-1 i ve t re a t  in c n t ge n c ral1 y 
includes suppleinental oxygen therapy, c ~ i i t i i i ~ i ~ ~ s  
positi\,e airway pressure. or mechanical ventilation. 
P h arm ac (3 1 ogi c ni a nage inc n t consist s p ri mai-i 1 y o f 
thcophylline or caffeine; closapram h)~drochloridc 
is a second-line agent that has also been given to 
s t i mu 1 a t  e t he rcsp I rat  o ry ccn t c I-. For t h e t reat men t 
o f a pn e a ,  the t h c' rape u I ic sc r u i n  t hen ph y 11 i ne 
concentration (SPC) ranges from 6.6-1 3 pg/ml.". ' 
The toxic effects of theophylline are dose related, 
ge n e ra 11 y p r o  g re s s i n g fro ni gas t ro i n t e s t in a 1 
disturbances to abnormalities of cardiovascular rate 
and rhythm, to central nervous system toxicity 
often manifested as intractable seizures.s 
The drug's half-life is prolonged in the newborn 
secondary to an immature cytochrome P450 (C- 
P450) system and ranges from 13-29 hours.s 
In t rapa t ien t  and  in te rpa t ien t  theophyl l ine  
metabolism varies considerably. Because of the low 
level of activity of the C-P450 system, the newborn 
methylates a portion of theophylline to caffeine, 
which has an even longer half-life, ranging from 
100-200 hours.' The additive pharmacologic 
effect of caffeine in the treatment of apnea, in 
conjunction with its extended half-life, complicates 
the dosing requirements of theophylline in the 
newborn. According to one group,' although the 
activity of the C-P450 system in the newborn 
increased from 28-42 weeks' postconceptional age 
(PCA), there was no concomitant decrease in the 
methylation of theophylline to caffeine. Therefore, 
it would be advantageous to identify predictors of 
theophylline dosing requirements in neonates. 
Although theophylline has been the mainstay of 
the pharmacologic  t rea tment  for apnea  of 
prematurity since the early 1970s, no consensus 
exists as to  the best  me thod  to  predict  the 
appropriate maintenance dosage in premature 
newborns. Numerous studies have evaluated the 
agent's pharmacokinetics in premature infants with 
apnea and led to the development of empiric 
dosage guidelines based on weight to include a 
loading dose of 5.0-6.0 mg/kg and a maintenance 
dosage of 1.1-2.0 mg/kg every 12 hours."-" 
We compared the accuracy, precis ion,  and  
reliability of two equations using postnatal age 
(PNA) to calculate the maintenance dosage of 
theophylline to an established standard maintenance 
dosage (SMD) that produced a serum theophylline 
concent ra t ion  (STC) of 8-10 pg/ml for the 
treatment of apnea of prematurity. 
Methods 
Infants less than 34 weeks' gestational age (GA) 
diagnosed with apnea of prematurity and requiring 
intra\mous aminophylline therapy u'ci-c screened 
between December 1992 and June 1993. They 
were enrolled i n  the study i f  they had initially 
reccivcd 6 m g k g  intravenous aminophyllinc as a 
loading dose, were not rccci\ring any other drugs 
such as phenoharbital t h a t  might influencc the 
clearance of theoph)'lline, had no  significant 
perinatal events that could affect theophylline 
metabolism (e.g., birth asphyxia), and had normal 
renal and hepatic function. Since the STC was 
measured as part of routine patient care and data 
collection was retrospecti\Te, informed consent was 
not required by the investigational review board, 
which approved the study. 
The initial maintenance dosage of aminophylline 
corresponded to PNA. Premature infants 30 days 
PNA or younger received 1.6 mg/kg intravenously 
every 12 hours ,  and those over 30  days PNA 
received 2.4 mg/kg intravenously every 12 hours. 
All doses were infused over 15-30 minutes using a 
syringe pump, and a steady-state trough STC was 
obtained for all subjects. 
Steady-state condition was defined as that point 
at which the patient had received a loading dose 
followed by at least four maintenance doses before 
a trough STC was obtained, based on an assumed 
half-life of 13-29 hours. If this steady-state STC 
was less than the desired trough STC of 8 pg/ml, 
the midtherapeutic range for treatment of apnea of 
prematurity, the initial maintenance dosage was 
adjusted using principles of first-order pharmaco- 
kinetics to reach this range. The new trough STC 
was determined after the patient had received at 
least four new maintenance doses. If the target 
level (8-10 pg/ml) was achieved, at this point the 
pa t ien t  was en tered  in  the  s tudy  and  data  
collection started. 
A fluorescence polarization immunoassay (TDx, 
Abbott Laboratories) was used to analyze all STCs. 
Data collected on each subject included PNA, PCA, 
GA, weight, STC, and the' actual dose required to 
reach therapeutic STC (8-10 pg/ml). 
Equations 
For the purpose of comparison with s tudy  
equations, the target STC was set at 8 pg/ml 
When a trough STC of 8-10 pg/ml was reached, 
the patient was entered into the study, and the 
dosage required to achieve the target trough STC of 
8 pg/mI (dcterniined h y  first-order kinetics) was 
ca lcu la ted .  This  u ~ a s  called t h e  s t anda rd  
maintenance dosage (SMD). It was then compared 
urith the dosage calculated b>r each of the follo\ving 
equations: 
and 
using the study populations PNX. 01  note is the 
fact that equation 1 is derilned from equation 2 by 
performing a 37% reduct ion in the constant  
parameters. Since equation 2 ~ v a s  designed to 
produce a STC of 10-20 pg/ml, one would expect 
equation 1 to produce a STC of 7-13 pg'ml. The 
dosages predicted by these two equations were 
analyzed for the precision, bias, and reliability with 
which they might predict the SMD calculated to 
produce a target trough STC of 8 pg/ml. 
mg/kg/da)g = l(0.2 s PNA in wks) + 51' 
rng/kg/day = l(0.3 x PNA in wks) + 81 ,Ii 
(1) 
(2) 
Data Analysis 
The squared prediction error (precision) of each 
equation to predict the SMD was calculated as 
follows. The theophylline dosage (mg/kg/day) 
predicted by equation 1 for each patient was 
subtracted from the SMD (mg/kg/day) and the 
absolute difference was squared. The mean of the 
sum of squared differences was determined and 
analyzed us ing  Student 's  t t e s t . ' '  The  same 
procedure was performed for equation 2.  The 
equation with the smaller mean difference was 
considered to be the more precise. The precision 
of the equations to predict the desired STC was 
also compared. The frequency with which they 
predicted a theophylline dosage, based on a linear 
relationship to the SMD, that would have produced 
a STC of 8-10 pg/ml was determined. These 
frequencies were compared using McNemar's x L  
analysis for correlated data. The equation with the 
h igher  percentage was cons idered  the more  
precise. 
Bias was determined by calculating the mean 
prediction error.'h The reliability of each equation 
to predict the SMD was determined by correlation 
analysis. The equation with the coefficient closest 
to 1 was considered to be more reliable. 
Results 
A total of 46 premature newborn infants were 
evaluated in a prospect ive manner  Patient 
demographics are presented in Table 1 The mean, 
standard deviations, and range of theophylline 
dosages calculated from equations 1 and 2 and 
SMD and the actual doses arc shown in Table 2 
Table 1, Patient Demographics 
Table 2. Standard and Predicted Doses of Theophylline 
Using Published Equations 
DCW hle'lrl (+ in) (Ill&$Cl'l>.) 
Ac1ual dosc 5.60 (1 09) 
';LID 5.73 ( 1  37) 
EC~""~I'311 1 5 (31 (0 15'1 
Ecluation 2 8 '11 (0 07) 
s41n = sl'll1Clal.d m'~lnli'nrln<c d<X'l::c 
The means of the squared absolute differences 
were 1.7 and 12.1 for equations 1 and 2, respectively. 
Equation 1 was significantly more accurate than 
equation 2 (Student's t Lest ~10.05). Equations 1 
and 2 predicted the desired STC in 46% and 2% of 
patients, respectilsely, indicating that equation 2 
was less precise than equation 1 (Mc Nemar's x' 
p<0.05). 
The SMD did not correlate with the maintenance 
dosages calculated by either equation (r=0.296 and 
0.296, p>0.05 in both cases). Because of the poor 
cor re la t ion ,  mul t ip le  l inear  regression was 
performed with the SMD l'ersus GA, PNA, and 
PCA, and also was not significant (r=0.33, p=0.32). 
Linear regression of the SMD versus PNA revealed 
a weak but significant correlation (r=0.3, p=0.04). 
Due to the weak correlations obtained with above 
variables and SMD, we used the same data to 
generate two new equations of the best fit line. 
Pearsoii correlation analysis was performed on 
two separate sets of data formed by stratifying the 
existing data based on GA. The stratified data 
included GA of 27-30 weeks or 31-34 weeks. For 
infants 27-30 weeks the correlation was poor 
( r=0.05;  p=0.78; mean square prediction error 
1.1). However, for infants 31-34 weeks' GA, the 
correlation although weak, was much improved 
(r=0.42;  p=0.05; mean square prediction error 
1.18). The predicted equations are as follows. 
27-30 weeks: 
mg/kg/day = 5.81- (0.02 x PNA in wks) 
31-34 weeks: 
(A) 
and 
mg/kg/day =4.82+ (0.28 x PNA in wks) (B) 
Discussion 
Currently, a number of dosage guidelines are 
available for calculating theophylline niaintenance 
dosages in newborns a n d  infanls. However, they 
inust be evaluated because 0 1  the wide iwialiility 
of the patient populations, closing inter\&, and 
routes  and  me thods  of adminis t ra t ion  ( i . e . ,  
in t e r m i t t e n t \'s c on tin uo us in lusi ans) . Th c Food 
an tl Drug A d  ni i 1-11 s I i-a t 1 on re c CI ni ni e n d s a 1 oa di ng 
dose of 1 mg/kg theoph>,lline for each 2-\ig/ml 
increasc in STC dcsired, folln\vcd by 1 .O nig/kg 
every 12 hours maintenance for preterm infants 
(I 36 weeks PCA). For full-term infants (either at 
birth or 40 wks PCA) the recommended dosage is 
1-2 ing/kg every 12 hours ."  These guidelines 
generally result in subtherapeutic STCs.' " I '  
Alternative methods for calculating theophylline 
maintenance dosages in newborns have been 
proposed. An alternative for infants less than 1 
year of age is an equation (equation 1) that also 
incorporates PNA in weeks as a variable.' I t  is 
designed to achieve a therapeutic STC of 7-13 
pg/ml. Although there is no primary reference for 
it or targeted STC in the literature, this equation, 
which is a modification of the equation derived by 
Hendeles et al,lq is a 37% reduction of the original 
one derived by Nassif et a1,li presumably expected 
to produce a trough STC that is 37% less than that 
produced by the equation of Nassif (i.e., 37% of 
10-20 pg/ml, which is 7-13 pg/ml). This original 
equation (equation 2) was obtained from the least 
squares regression of the oral theophylline dose in 
nig/kg/day versus PNA in weeks in infants 6-48 
weeks' PNA being treated for asthma. It aimed for 
STC of 10-20 pg/ml and produced a mean STC of 
approximately 15 pg/ml. For the very premature 
infant this STC could be toxic and produce side 
effects such as tachycardia. 
Another studylo compared three equations that 
incorporated either PNA or PCA to determine the 
maintenance theophylline dosage after continuous 
intravenous infusion. The dose based on PNA was 
the most accurate in producing STCs of 10-20 
pg/ml in infants ranging from 4.5-54.3 weeks' 
PNA. 
The  majori ty  of equat ions  that  have been  
evaluated to date for accuracy of theophylline 
dosing are either empiric or incorporate PNA as 
the only patient-specific variable, which may not 
be sufficient to individualize therapy in the 
premature infant. The age range of the patients 
studied and the therapeutic STCs obtained in these 
s tud ies  are also different from the variables 
primarily in\rolved in treating apnea of prematurity 
(i.e.. PCA < 40 Lvks, STC 6-12 pg/nil) 
The accuracy of equat ion  1 is statistically 
significantly beltel- than that of equation 2.  Its 
precision is also better for predicting maintenance 
dosages that yield STCs of 8-10 kig/inl. The results 
o I our  study i 11 d i ca t c that t 1 c se e y u a t 1 o 11 s f c, 1- 
dosing theophylline in newborns are not reliable 
and correlated poorly in our study population. We 
subsequent l i ,  cleri\red equat ions  X and B l o r  
premature newborns based on GA and PNA. They 
were generated from the best f i t  lines of the 
regression oC PNA and the SMD after stratifying the 
data for GA 27-30 and 31-34 weeks. The SMD of 
theophylline for premature newborns with apnea 
of prematurity that they predict is expected t o  
achieve a desired therapeutic STC of approximately 
8-10 pg/ml. Our patient population is homo- 
geneous and the target STC is narrow. Both of 
these factors provide a more accurate and safer 
prediction of theophylline maintenance dosage for 
treatment of apnea of prematurity I t  is probable 
that the difference observed between equations A 
and B may be related to differences in the degree of 
maturation of the cytochrome P-450 system as a 
function of gestational age. 
We realize that the correlation for these newly 
generated equations, especially for infants less than 
30 weeks, is weak. However, we intend to evaluate 
their utility and accrue data to see if we can 
develop better ones. 
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